The role of PD-1/PD-L1 checkpoint in arsenic lung tumorigenesis

被引:7
|
作者
Xu, Wenhua [1 ,2 ]
Cui, Jiajun [1 ,3 ]
Wu, Linqing [1 ,4 ]
He, Caigu [1 ,5 ]
Chen, Gang [1 ]
机构
[1] Univ Kentucky, Dept Pharmacol & Nutr Sci, Coll Med, MN306,800 Rose St, Lexington, KY 40536 USA
[2] Univ Sci & Technol China, Dept Neurol, Affiliated Hosp 1, Hefei 230001, Anhui, Peoples R China
[3] Yichun Univ, Coll Med, Dept Biochem, Yichun 336000, Jiangxi, Peoples R China
[4] Fujian Med Univ, Sch Basic Med Sci, Dept Immunol, Fuzhou 350003, Fujian, Peoples R China
[5] Fujian Univ Tradit Chinese Med, Dept Histol & Embryol, Fuzhou 361000, Fujian, Peoples R China
关键词
Arsenic; Lung; Tumor; T cell; PD-1; PD-L1; REGULATORY T-CELLS; CANCER; CD8(+); EXHAUSTION; PROLIFERATION; IMMUNOTHERAPY; LYMPHOCYTES; EXPRESSION; MODELS; PD-L1;
D O I
10.1016/j.taap.2021.115633
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic exposure to environmental arsenic promotes lung cancer. Emerging evidence indicates that compromised host immunity, particularly T cell anti-tumor immunity, may play a critical role in cancer development. However, there is a knowledge gap in terms of the effects of arsenic exposure on T cell anti-tumor immunity and how that may contribute to arsenic lung carcinogenicity. Immunosuppression has been known as a risk factor for many types of cancer, including lung cancer. The development of cancer indicates the success of immunosuppression and escape of cancer cells from host anti-tumor immunity in which T cells are the major component. The anti-tumor immunity is mainly executed by CD8 cytotoxic T cells through their anti-tumor effector function, which can be regulated by immune checkpoint pathways. Some inhibitory receptors on the T cell membrane and their ligands form these pathways, among which programmed death-1 (PD-1), a T cell inhibitory receptor, and its ligand, programmed death-ligand 1 (PD-L1), are best characterized. A/J mice are naturally sensitive to pulmonary carcinogens, prone to develop spontaneous lung tumors later in life and have been frequently used as an animal model for lung tumorigenesis research. Chronic arsenic administration through drinking water has been shown to enhance tumor formation in the lungs of A/J mice. In the current study, using this mouse model we want to determine whether PD-1/PD-L1 plays a role in arsenic-enhanced lung tumorigenesis. The results showed that prolonged arsenic exposure up-regulated PD-1/PD-L1, increased regulatory T cells (Tregs), decreased CD8/ Treg ratio, inhibited T cell antitumor function in the lungs and enhanced lung tumor formation, while inhibition of PD-1/PD-L1 restored CD8/Treg ratio and T cell anti-tumor effector function, and mitigated arsenic-enhanced lung tumorigenesis. In addition, inhibition of PD-1/PD-L1 could be a potential preventive strategy to mitigate the tumorigenic action of chronic arsenic exposure.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
    Baraibar, Iosune
    Melero, Ignacio
    Ponz-Sarvise, Mariano
    Castanon, Eduardo
    DRUG SAFETY, 2019, 42 (02) : 281 - 294
  • [42] Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction
    Le Biannic, Raphael
    Magnez, Romain
    Klupsch, Frederique
    Leleu-Chavain, Natascha
    Thiroux, Bryan
    Tardy, Morgane
    El Bouazzati, Hassiba
    Dezitter, Xavier
    Renault, Nicolas
    Vergoten, Gerard
    Bailly, Christian
    Quesnel, Bruno
    Thuru, Xavier
    Millet, Regis
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 236
  • [43] Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
    Sharma, Meenal
    Yang, Zhiming
    Miyamoto, Hiroshi
    MEDICINE, 2019, 98 (38)
  • [44] Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy
    Song, Yue
    Li, Zhaoming
    Xue, Weili
    Zhang, Mingzhi
    IMMUNOTHERAPY, 2019, 11 (06) : 515 - 529
  • [45] Combination of PD-1/PD-L1 checkpoint blockade and dendritic cell therapy
    Nesselhut, J.
    Marx, D.
    Lange, H.
    Chang, R. Y.
    Nesselhut, T.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2018, 48 : 95 - 95
  • [46] The role of intestinal flora on tumorigenesis, progression, and the efficacy of PD-1/PD-L1 antibodies in colorectal cancer
    Sen Wang
    Benling Xu
    Yangyang Zhang
    Guangyu Chen
    Peng Zhao
    Quanli Gao
    Long Yuan
    Cancer Biology & Medicine, 2024, 21 (01) : 65 - 82
  • [47] The role of intestinal flora on tumorigenesis, progression, and the efficacy of PD-1/PD-L1 antibodies in colorectal cancer
    Wang, Sen
    Xu, Benling
    Zhang, Yangyang
    Chen, Guangyu
    Zhao, Peng
    Gao, Quanli
    Yuan, Long
    CANCER BIOLOGY & MEDICINE, 2024, 21 (01) : 65 - 82
  • [48] Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
    Lipson, Evan J.
    Lilo, Mohammed T.
    Ogurtsova, Aleksandra
    Esandrio, Jessica
    Xu, Haiying
    Brothers, Patricia
    Schollenberger, Megan
    Sharfman, William H.
    Taube, Janis M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [49] PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
    Katerina Ancevski Hunter
    Mark A. Socinski
    Liza C. Villaruz
    Molecular Diagnosis & Therapy, 2018, 22 : 1 - 10